Table 1.

In vitro antibacterial effect of ebselen on Gram-positive bacteria and mycobacteria.

Microorganism		Strain	MIC (μg/mL)	Reference
E. faecium		Clinical {27}	2∗	[58]
S. aureus		Clinical {5}	0.25–1	[54]
Enterococcus spp.		VRE	64	[46]
S. aureus		MRSA	64
		MSSA	0.5
S. aureus		Clinical	2.2	[55]
Bacillus spp.	B. cereus	ATCC 14579	0.9	[56]
	B. subtilis	ATCC 6633	0.14
S. aureus		ATCC 29213	1.1
M. tuberculosis		H37 Rv	10
M. tuberculosis		H37 Rv	20	[15]
S. aureus		USA 300/400	0.25	[57]
E. faecalis		Clinical {39}	0.78∗	[43]
Staphylococcus spp.	S. aureus	MRSA {60}	1.56∗
	CNS	Clinical {33}	0.78∗
Staphylococcus spp.	S. aureus	ATCC 25923	34	[32]
	S. simulans	103P	55
Staphylococcus spp.	S. aureus	MRSA {11}	0.125–0.5	[16]
		Linezolid-resistant S. aureus (NRS 119)	0.125
		Mupirocin-resistant S. aureus (NRS 107)	0.125
		VRSA {11}	0.125–0.5
		MSSA (ATCC 6538)	0.125
	S. epidermidis	NRS 101	0.5
Enterococcus spp.	E. faecalis	ATCC (49533, 7080, 49532, 14506, and 51229) (VRE)	0.25–1.0	[52]
		SF 24397/24413	0.125
		SF28073	0.625
		HH22/MMH 594/SV587 (VRE)	0.125
	E. faecium	E1162	0.25
		E0120 (VRE)/ERV102 (VRE)	0.5
		ATCC 6569 and ATCC 700221 (VRE)	0.5–1
Staphylococcus spp.	S. aureus	MRSA {6}	0.125–0.25
		MSSA {2}	0.25
		VISA {2}	0.125–0.25
		VRSA {4}	0.125–0.25
Streptococcus spp.	S. pyogenes	ATCC 1234	0.5
	S. agalactiae	MNZ (938, 933, and 929)	0.5
Enterococcus spp.	E. faecalis	ATCC 51229 (VRE)	0.5	[53]
	E. faecium	ATCC 700221 (VRE)
Staphylococcus spp.	S. aureus	VRSA {15}/MRSA {15}	0.125–0.5
		MSSA {4}/VISA {3}	0.125–0.25
	S. epidermidis	NRS 101	0.5
M. tuberculosis		H37Rv	100∗∗	[59]
		XDR and MDR clinical isolates	50∗∗

{ }: number of isolates; ^∗MIC₉₀; ^∗∗μM; VRSA: vancomycin-resistant Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus aureus; MSSA: methicillin-susceptible Staphylococcus aureus; VISA: vancomycin-intermediate Staphylococcus aureus; VRE: vancomycin-resistant Enterococcus spp.; ATCC: American Type Culture Collection.